Clinical Trial Update: A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating E7777 in combination with CHOP for first-line treatment of peripheral T-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• E7777 (E7777)

Snippet

Sponsor: Eisai Inc. | Conditions: Peripheral T-Cell Lymphoma | Phase 3 | Status: WITHDRAWN